Pular para o conteúdo
Merck
Todas as fotos(1)

Key Documents

Y0000853

Fluvoxamine for system suitability

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

Fluvoxamine maleate, (E)-5-Methoxy-1-[4-(trifluoromethyl)phenyl]-1-pentanone-O-(2-aminoethyl)oxime maleate

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C15H21F3N2O2 · C4H4O4
Número CAS:
Peso molecular:
434.41
Número MDL:
Código UNSPSC:
41116107
ID de substância PubChem:
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

fluvoxamine

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

formato

neat

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

COCCCC/C(C1=CC=C(C(F)(F)F)C=C1)=N\OCCN.OC(/C=C\C(O)=O)=O

InChI

1S/C15H21F3N2O2.C4H4O4/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18;5-3(6)1-2-4(7)8/h5-8H,2-4,9-11,19H2,1H3;1-2H,(H,5,6)(H,7,8)/b20-14+;2-1-

chave InChI

LFMYNZPAVPMEGP-PIDGMYBPSA-N

Informações sobre genes

human ... SLC6A4(6532)

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Fluvoxamine for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

Pictogramas

Exclamation mark

Palavra indicadora

Warning

Frases de perigo

Declarações de precaução

Classificações de perigo

Acute Tox. 4 Oral

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Lamentamos, não temos COA para este produto disponíveis online no momento.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Donatella Marazziti et al.
Human psychopharmacology, 27(4), 397-402 (2012-07-19)
In this study, we explored the possible relationships between plasma fluvoxamine levels and clinical features and/or response in adult obsessive-compulsive disorder (OCD) patients treated with this drug for 6 months. Twenty OCD outpatients of both sexes who were already taking
Anton J L M van Balkom et al.
Psychotherapy and psychosomatics, 81(6), 366-374 (2012-09-12)
To compare the effectiveness of second-step treatment with cognitive therapy (CT) versus fluvoxamine in patients with obsessive-compulsive disorder (OCD) who are nonresponsive to exposure in vivo with response prevention (ERP). A 12-week randomized controlled trial at an outpatient clinic in
Tomihisa Niitsu et al.
Journal of clinical psychopharmacology, 32(5), 593-601 (2012-08-29)
Cognitive impairments in schizophrenia are associated with suboptimal psychosocial performance. Several lines of evidence have suggested that endoplasmic reticulum protein sigma-1 receptors were involved in cognitive impairments in patients with schizophrenia and that the sigma-1 receptor agonist fluvoxamine was effective
Md Shenuarin Bhuiyan et al.
Journal of pharmacological sciences, 121(3), 177-184 (2013-02-23)
Depression is associated with a substantial increase in the risk of developing heart failure and is independently associated with increased cardiovascular morbidity and mortality. Inversely, cardiovascular disease can lead to severe depression. Thus, therapy with selective serotonin reuptake inhibitors (SSRIs)
Shohei Matsunami et al.
Behavioural brain research, 233(2), 577-586 (2012-06-12)
Behavioural effects of fluvoxamine (FLV, selective serotonin reuptake inhibitor) were examined in 1-2 week old domestic chicks. Chicks were tested in an I-shaped maze equipped with a feeder (ON feeder) that served 1 or 2 grains of millet at gradually

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica